Format

Send to

Choose Destination
Ann Oncol. 2016 Feb;27(2):225-32. doi: 10.1093/annonc/mdv560. Epub 2015 Nov 16.

Strategies for clinical implementation of TNM-Immunoscore in resected nonsmall-cell lung cancer.

Author information

1
Department of Oncology, University Hospital of North Norway, Tromso Institute of Clinical Medicine, The Arctic University of Norway, Tromso tom.donnem@uit.no.
2
Department of Oncology, University Hospital of North Norway, Tromso.
3
Department of Clinical Pathology, University Hospital of North Norway, Tromso Institute of Medical Biology, The Arctic University of Norway, Tromso.
4
Department of Oncology, University Hospital of North Norway, Tromso Institute of Clinical Medicine, The Arctic University of Norway, Tromso.
5
Institute of Clinical Medicine, The Arctic University of Norway, Tromso.
6
Department of Oncology, Oslo University Hospital, The Norwegian Radium Hospital, Oslo.
7
Department of Oncology, Oslo University Hospital, The Norwegian Radium Hospital, Oslo Department of Cancer Genetics, Oslo University Hospital, The Norwegian Radium Hospital, Oslo.
8
Department of Pathology, Oslo University Hospital, The Norwegian Radium Hospital, Oslo.
9
Department of Cardiothoracic Surgery, Oslo University Hospital, Rikshospitalet, Oslo.
10
The Cancer Clinic, St Olavs Hospital, Trondheim University Hospital, Trondheim Department of Cancer Research and Molecular Medicine, European Palliative Care Research Centre, Norwegian University of Science and Technology, Trondheim.
11
Department of Pathology and Medical Genetics, St Olavs Hospital-Trondheim University Hospital, Trondheim.
12
Department of Pathology, Haukeland University Hospital, Bergen, Norway.
13
Department of Thoracic Medicine, Haukeland University Hospital, Bergen, Norway.
14
Department of Oncology, Rigshospitalet, Copenhagen, Denmark.
15
Department of Pathology, Nordland Hospital, Bodo.
16
Department of Community Medicine, The Artic University of Tromso, Tromso, Norway.
17
Nuffield Department of Clinical Laboratory Sciences, University of Oxford, John Radcliffe Hospital, Oxford, UK.

Abstract

Immunoscore is a prognostic tool defined to quantify in situ immune cell infiltrates and appears highly promising as a supplement to the tumor-node-metastasis (TNM) classification of various tumors. In colorectal cancer, an international task force has initiated prospective multicenter studies aiming to implement TNM-Immunoscore (TNM-I) in a routine clinical setting. In breast cancer, recommendations for the evaluation of tumor-infiltrating lymphocytes (TILs) have been proposed by an international working group. Regardless of promising results, there are potential obstacles related to implementing TNM-I into the clinic. Diverse methods may be needed for different malignancies and even within each cancer entity. Nevertheless, a uniform approach across malignancies would be advantageous. In nonsmall-cell lung cancer (NSCLC), there are several previous reports indicating an apparent prognostic importance of TILs, but studies on TILs in a TNM-I setting are sparse and no general recommendations are made. However, recently published data is promising, evoking a realistic hope of a clinical useful NSCLC TNM-I. This review will focus on the TNM-I potential in NSCLC and propose strategies for clinical implementation of a TNM-I in resected NSCLC.

KEYWORDS:

NSCLC; T cells; TNM-I; immunoscore; lung cancer

PMID:
26578726
DOI:
10.1093/annonc/mdv560
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center